ARVN Live signaler | Maksimer profitt med Getagraph.com

KJøP 115197 min ago

@ $49.33

Utstedt: 14 feb 2024 @ 21:32

Avkastning: -33.46%

Forrige signal: feb 14 - 16:03

Forrige signal: Selg

Avkastning: 2.08 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins...

Stats
Dagens volum	415 371
Gjennomsnittsvolum	763 969
Markedsverdi	2.24B
EPS	$-2.53 ( 2024-05-03 )
Neste inntjeningsdato	( $-1.410 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.96
ATR14	$0.0410 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Berkowitz Noah	Buy	93 879	Stock Option (right to buy)
2024-03-18	Berkowitz Noah	Buy	63 452	Common Stock
2024-03-18	Berkowitz Noah	Buy	0
2024-02-29	Teel Randy	Sell	0	Common Stock
2024-02-29	Teel Randy	Sell	0	Common Stock

INSIDER POWER
45.44
Last 95 transactions
Buy: 1 590 588 \| Sell: 490 115

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: -0.77 (moderate negative)

Signal:(36.362) Neutral

Arvinas Inc Korrelasjon

10 Mest positive korrelasjoner
WSC	0.911
XMTR	0.905
PRSO	0.902
TRS	0.899
GMBL	0.898
SELB	0.898
SPTN	0.898
AMNB	0.897
ROIC	0.896
ESSA	0.895

10 Mest negative korrelasjoner
TVTY	-0.902
WLTW	-0.898
BTAQ	-0.897
SGEN	-0.893
USLM	-0.891
GPACU	-0.887
FRSG	-0.885
NVSA	-0.883
GVCI	-0.883
MLAI	-0.881

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Arvinas Inc Korrelasjon - Valuta/Råvare

-0.34
( neutral )

-0.42
( neutral )

0.00
( neutral )

-0.13
( neutral )

-0.29
( neutral )

-0.11
( neutral )

Arvinas Inc Økonomi

Annual	2023
Omsetning:	$78.50M
Bruttogevinst:	$71.80M (91.46 %)
EPS:	$-6.62

FY	2023
Omsetning:	$78.50M
Bruttogevinst:	$71.80M (91.46 %)
EPS:	$-6.62

FY	2022
Omsetning:	$131.40M
Bruttogevinst:	$123.20M (93.76 %)
EPS:	$-5.11

FY	2021
Omsetning:	$46.00M
Bruttogevinst:	$46.00M (100.00 %)
EPS:	$-3.82

Financial Reports:

No articles found.

Arvinas Inc

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.